Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Paclitaxel

abstract

  • Paclitaxel's clinically significant activity against metastatic breast cancer extends to patients with many prior chemotherapy regimens. The lack of impact of prior doxorubicin therapy on the likelihood of subsequent response to paclitaxel suggests an important role for this agent in the treatment of refractory metastatic breast cancer.

publication date

  • May 1995

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7537798

Additional Document Info

start page

  • 1152

end page

  • 9

volume

  • 13

number

  • 5